and full-service, vascular, clinical research organisation (CRO) Vastrax have announced a strategic collaboration to expedite enrolment in clinical trials for research on new neurovascular therapies.

Viz RECRUIT software will become the artificial intelligence (AI)-powered clinical trial recruitment platform of Vastrax for its neurovascular trials.

The software has been designed to identify eligible patients for the trials by scanning their images in real-time.

This will enable round-the-clock identification of potential study subjects automatically, and notifications will be sent to research teams.

The Cloud-based technology of expands the recruitment funnel in size, as well as diversity, and streamlines the trial enrolment workflow. chief clinical officer Jayme Strauss said: “We are pleased to partner with Vastrax to advance important clinical research.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Viz’s AI-powered recruitment software, combined with Vastrax’s deep expertise in neurovascular and vascular clinical trials, will help increase access and diversity in research to get new therapies to patients faster.”

Under the partnership, the companies will enable an accelerated and enhanced enrolment of clinical trials and a quicker route to market for new neurovascular devices.

Vastrax president Ryan Bouchard said: “We believe that, together with the Viz RECRUIT platform, Vastrax’s clients will more quickly enrol a broader patient population in their clinical trials, enabling accelerated market access and potentially broader indications.

“This will enable a big leap in endovascular trial execution, with the view to more patients safely accessing new technologies faster.”

In February 2020, announced new algorithms and expanded features for its Viz RECRUIT clinical trial platform, which offers new algorithms for intracerebral haemorrhage detection, aneurysm detection, and Ischemic Core Volumes.